SG10201709388QA - Pharmaceutical formulations for subcutaneous administration of furosemide - Google Patents

Pharmaceutical formulations for subcutaneous administration of furosemide

Info

Publication number
SG10201709388QA
SG10201709388QA SG10201709388QA SG10201709388QA SG10201709388QA SG 10201709388Q A SG10201709388Q A SG 10201709388QA SG 10201709388Q A SG10201709388Q A SG 10201709388QA SG 10201709388Q A SG10201709388Q A SG 10201709388QA SG 10201709388Q A SG10201709388Q A SG 10201709388QA
Authority
SG
Singapore
Prior art keywords
furosemide
pharmaceutical formulations
subcutaneous administration
subcutaneous
administration
Prior art date
Application number
SG10201709388QA
Inventor
Scott A Michaels
Pieter Muntendam
Glenn R Larsen
Original Assignee
Scpharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361808962P priority Critical
Application filed by Scpharmaceuticals Inc filed Critical Scpharmaceuticals Inc
Publication of SG10201709388QA publication Critical patent/SG10201709388QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfasalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
SG10201709388QA 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide SG10201709388QA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201361808962P true 2013-04-05 2013-04-05

Publications (1)

Publication Number Publication Date
SG10201709388QA true SG10201709388QA (en) 2017-12-28

Family

ID=51659206

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201508251RA SG11201508251RA (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide
SG10201709388QA SG10201709388QA (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201508251RA SG11201508251RA (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Country Status (11)

Country Link
US (3) US9884039B2 (en)
EP (1) EP2981258B1 (en)
JP (2) JP6415535B2 (en)
KR (1) KR20160014592A (en)
CN (1) CN105431145B (en)
AU (1) AU2014248164B2 (en)
CA (1) CA2908935A1 (en)
HK (1) HK1221152A1 (en)
MX (1) MX367165B (en)
SG (2) SG11201508251RA (en)
WO (1) WO2014165660A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014115951A1 (en) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Compositions containing finafloxacin and tris
WO2020120482A1 (en) * 2018-12-10 2020-06-18 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
WO2020160210A1 (en) * 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
JP3267613B2 (en) * 1991-05-30 2002-03-18 アボツト・ラボラトリーズ Reagents containing non-specific binding blockers in ion capture binding assays
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
IT1283608B1 (en) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Pharmaceutical composition for oral diuretic and antihypertensive therapy.
CN1068778C (en) * 1998-05-15 2001-07-25 赵超英 Novel drug composition for treating and curing and its preparing method
EP1803934B1 (en) 2005-12-28 2008-09-24 Sensile Pat AG Micropump
ES2780193T3 (en) * 2006-07-12 2020-08-24 Univ Tennessee Res Found Compound to treat breast cancer and progestin-dependent conditions
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
MX2010012450A (en) * 2008-05-16 2011-03-21 Corthera Inc Star Treating dyspnea associated with acute heart failure with relaxin.
JP5661630B2 (en) * 2008-09-09 2015-01-28 シマ ラブス インク. Weak ionic compound dosage forms
MX2012002762A (en) * 2009-09-04 2012-06-12 Minipumps Llc Adhesive skin patch with pump for subcutaneous drug delivery.
EP3556749A1 (en) 2011-10-19 2019-10-23 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation

Also Published As

Publication number Publication date
US9884039B2 (en) 2018-02-06
HK1221152A1 (en) 2017-05-26
EP2981258A4 (en) 2016-10-05
US10272064B2 (en) 2019-04-30
CN105431145B (en) 2019-12-10
JP6677779B2 (en) 2020-04-08
JP6415535B2 (en) 2018-10-31
US20180303790A1 (en) 2018-10-25
EP2981258A1 (en) 2016-02-10
KR20160014592A (en) 2016-02-11
WO2014165660A1 (en) 2014-10-09
US20200038364A1 (en) 2020-02-06
US20160051507A1 (en) 2016-02-25
JP2019001821A (en) 2019-01-10
AU2014248164B2 (en) 2019-05-23
AU2014248164A1 (en) 2015-10-15
SG11201508251RA (en) 2015-11-27
CN105431145A (en) 2016-03-23
MX367165B (en) 2019-08-07
EP2981258B1 (en) 2020-08-12
MX2015014064A (en) 2017-04-13
JP2016515623A (en) 2016-05-30
CA2908935A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
DK3146515T3 (en) System and method of pharmaceutical storage, delivery and administration
HK1218850A1 (en) Sustained drug delivery implant
IL240792D0 (en) Integrated continuous manufacturing of therapeutic protein drug substances
HK1221672A1 (en) Nasal administration
HK1205690A1 (en) Pharmaceutical composition and administration thereof
BR112015000529A2 (en) dry powder drug delivery methods and systems
IL245211D0 (en) Medicament inhaler
HK1213503A1 (en) Drug delivery medical device
IL244259D0 (en) Delivery of medical devices
EP2991711A4 (en) Drug delivery device
SG10201609982PA (en) Pharmaceutical formulations of tnf-alpha anitbodies
RU2015146211A (en) Microspheric medicinal delivery system for slow-in-organic discharge
HK1222122A1 (en) Selective drug delivery compositions and methods of use
IL264413D0 (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
RU2016122908A (en) Compounds of dihydropyrimidine and their application in pharmaceutical drugs
HK1218392A1 (en) Tamper resistant pharmaceutical formulations
EP2968071A4 (en) Device for oral delivery of therapeutic compounds
DK2844222T3 (en) Pharmaceutical formulation with delayed delivery
RU2015143540A (en) A microchip for the delivery of a medicinal product and methods of its use
RU2015129522A (en) Medicinal delivery device
HK1219096A1 (en) Tamper resistant pharmaceutical formulations
ZA201504582B (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
IL243714D0 (en) Multi-unit drug delivery devices and methods
RU2015139934A (en) Devices for delivery of medicines with the component permeable for the medicinal product and methods of delivery of medicines
EP2849770A4 (en) Pharmaceutical compositions for the delivery of substantially water-insoluble drugs